so if you look at it in detail
rare disease like FSGS has a higher COS from phase 2 to 3 sitting at around 50%! then phase 3 COS goes to 73%.
As i stated - 30% cos is about right for phase 2 trials like DKD however given it has already passed phase 2a i would suggest the COS for phase 2b would be higher, however i cant find any actual stats on this.
so if you look at it in detailrare disease like FSGS has a...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 31.5¢ | $1.333M | 4.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 727594 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 170412 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
32.0¢ |
Change
-0.015 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 33.5¢ | 31.5¢ | 2261030 | ||
| Last updated 15.51pm 26/04/2024 ? | |||||
| DXB (ASX) Chart |